Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,762.52
(
2.20%
)
US TECH 100
24,158.40
(
2.61%
)
Dow Jones
47,739.09
(
2.48%
)
Brent Oil
94.36
(
-6.77%
)
Bitcoin
71,113.74
(
-1.19%
)
News Focus
News Focus

Replies to post #84 on Seagen Inc (SGEN)

Replies to #84 on Seagen Inc (SGEN)
icon url

surf1944

09/13/10 8:27 AM

#85 RE: surf1944 #84

6:48AM Seattle Genetics: phase IIb clinical trial of lintuzumab in older patients with acute myeloid leukemia did not meet its primary endpoint of extending overall survival; co will discontinue its development program for lintuzuma (SGEN) 12.72 :